Details of the Drug Combination

General Information of Drug Combination (ID: DCVXXHQ)

Drug Combination Name

Chlorphenesin Oxyphenbutazone

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

Chlorphenesin DM3VZJQ

Oxyphenbutazone DMPZS7U

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 15.15

Bliss Independence Score: 15.15

Loewe Additivity Score: 20.14

LHighest Single Agent (HSA) Score: 20.17

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Chlorphenesin

Disease Entry	ICD 11	Status	REF
Injury	NA00-ND5Z	Approved	[2]
Muscular pain	FB56	Approved	[2]
Fungal infection	1F29-1F2F	Withdrawn from market	[2]

Indication(s) of Oxyphenbutazone

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Approved	[2]

Oxyphenbutazone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Modulator	[3]
------------------------------------------------------------------------------------

Oxyphenbutazone Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Increases Activity	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
4	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.